Table 1 Patient characteristics at the beginning of paclitaxel plus bevacizumab therapy.
Variables | Number of patients (%) |
|---|---|
Age, years, median (range) | 62.0 (32–89) |
ER status | |
Positive | 82 (71.9) |
Negative | 32 (28.1) |
Diagnosis | |
Advanced | 44 (38.6) |
Recurrence | 70 (61.4) |
Metastatic sites | |
CNS | 10 (8.8) |
Bone | 61 (53.5) |
Lungs | 55 (48.2) |
Pleura and/or lymphangiopathy | 46 (40.4) |
Lymph node | 90 (78.9) |
Liver | 53 (46.5) |
Soft tissue | 73 (64.0) |
Type of metastases | |
Visceral | 93 (81.6) |
Non-visceral | 21 (18.4) |
Number of metastatic sites, median (range) | 3.5 (1–8) |
Number of metastatic sites | |
≥ 3 | 93 (81.6) |
< 3 | 21 (18.4) |
Prior (neo) adjuvant chemotherapy* | |
Yes | 37 (32.5) |
No | 77 (67.5) |
Disease-free interval | |
< 24 months | 67 (58.8) |
≥ 24 months | 47 (41.2) |
Number of previous chemotherapies | |
0–1 | 89 (78.1) |
≥ 2 | 25 (21.9) |
